IGF1R and cancer: This study has provided novel findings demonstrating that the high co-expression of IGF1R and SphK1 may have positive prognostic significance for overall (but not disease free) survival in ER-positive breast cancer, but in line with pre-clinical findings demonstrating IGF1R and SphK1 can promote oncogenic effects in cancer, paradoxically may still be considered for therapeutic targeting [6].